{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:33:23Z","timestamp":1784637203837,"version":"3.55.0"},"reference-count":104,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T00:00:00Z","timestamp":1244592000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ovarian cancer is today the most lethal female cancer with an overall survival of only 49.9%. The currently available screening modalities are disappointing in detecting highly curable early stage ovarian cancer. Natural history of ovarian cancer is unknown; it appears it can develop quickly from normal looking ovaries. Timely referral of women with non\u2010specific symptoms (such as abdominal bloating, pelvic pain) for an ultrasound scan or blood CA125 assessments may help in the early diagnosis. Patients with Stage IA or IB disease with grade 1 tumors have a cure rate of &gt;90%; this is likely to be compromised by laparoscopic surgery. In selected patients fertility preservation with good obstetric outcome is possible. However, the relapse rate in \u2018high risk\u2019 early stage ovarian cancers is 40\u201345%; adjuvant chemotherapy is needed. Only 20\u201325% of those with stage III and IV disease are cured. Despite a high primary response (70%) majority (70\u201375%) will relapse and all are likely to succumb. Optimal debulking surgery followed by adjuvant chemotherapy are needed for stages III and IV disease; the outcome is superior if managed by gynecologic oncologists. Where cost of drugs is an important consideration, an alternative is carboplatin (an affordable and equally effective drug). The role of vaccines needs further study. When relapses occur palliation will be the aim in most instances. Oral contraceptives, breast feeding, tubal sterilization and hysterectomy also have a protective effect. Risk\u2010reducing salpingo\u2010oopherectomy has been suggested in women with BRCA mutations.<\/jats:p>","DOI":"10.1111\/j.1447-0756.2009.01049.x","type":"journal-article","created":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T09:58:46Z","timestamp":1244627926000},"page":"393-404","source":"Crossref","is-referenced-by-count":2,"title":["Third S. S. Ratnam Memorial Lecture 2007. Ovarian cancer: Is there hope for women?"],"prefix":"10.1111","volume":"35","author":[{"given":"Vallipuram","family":"Sivanesaratnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_10_3_2","unstructured":"LimGCC HalimahY LimTO(Eds).Cancer incidence in Malaysia. First Report of the National Cancer Registry. Kualas Lumpur.2002."},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004320000153"},{"key":"e_1_2_10_5_2","first-page":"453","article-title":"Ovarian cancer mortality among immigrants in Australia and Canada","volume":"4","author":"Kliewer EV","year":"1995","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/oem.59.4.257"},{"issue":"1","key":"e_1_2_10_7_2","first-page":"261","article-title":"Carcinoma ovary. 26th Annual Report (FIGO) on the results of treatment in gynecological cancer. Pecorelli S (ed.)","volume":"95","author":"Heintz APM","year":"2006","journal-title":"Int J Gynecol Obstet"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)06071-0"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0847"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.05.005"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90351-0"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10261-1"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-200609000-00004"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.955"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.6642"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1879-3479.1979.tb00152.x"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2705"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200108000-00006"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2006.01153.x"},{"key":"e_1_2_10_20_2","volume-title":"2007 State of the State of Gynecologic Cancers","author":"Gynaecological Cancer Foundation USA","year":"2007"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(92)90164-T"},{"key":"e_1_2_10_22_2","first-page":"681","article-title":"Ovarian cancer in women with prior hysterectomy \u2013 A 14\u2010year experience at University of Miami","volume":"78","author":"Sightler S","year":"1991","journal-title":"Obstet Gynecol"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1999.tb08126.x"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.01.041"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(02)00104-X"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03340220040030"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.08.003"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2005.15203.x"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.1998.tb00074.x"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(94)90105-8"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6133"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/01443610500278097"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011101)92:9<2412::AID-CNCR1590>3.0.CO;2-7"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6805"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603273141302"},{"key":"e_1_2_10_36_2","first-page":"885","article-title":"Donor eggs. Their application in modern reproductive technologies","volume":"47","author":"Rosenwake Z","year":"1987","journal-title":"Fertil Steril"},{"key":"e_1_2_10_37_2","first-page":"566","article-title":"The concept of uterine preservation with ovarian malignancies","volume":"78","author":"Novot D","year":"1991","journal-title":"Obstet Gynecol"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197612)38:6<2404::AID-CNCR2820380629>3.0.CO;2-3"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02508-5"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.2820710425"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(86)90075-2"},{"key":"e_1_2_10_42_2","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Grifiths CT","year":"1975","journal-title":"Natl Cancer Monogr"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.01.029"},{"key":"e_1_2_10_44_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5926"},{"key":"e_1_2_10_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(92)90100-W"},{"key":"e_1_2_10_46_2","first-page":"195","article-title":"Primary surgical therapy for ovarian cancer: How much and when?","author":"Potter ME","year":"1992","journal-title":"Gynecol Oncol"},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"e_1_2_10_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.07.045"},{"key":"e_1_2_10_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1048-891X.2005.15003.x"},{"key":"e_1_2_10_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503093321002"},{"key":"e_1_2_10_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041125"},{"key":"e_1_2_10_52_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1622.1999.01484.x"},{"key":"e_1_2_10_53_2","first-page":"155","article-title":"Principles of cancer biology in relation to minimal access surgical techniques","volume":"2","author":"Greene FL","year":"1995","journal-title":"Semin Laparosc Surg"},{"key":"e_1_2_10_54_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2000.106053"},{"key":"e_1_2_10_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(98)70494-6"},{"key":"e_1_2_10_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(98)00323-8"},{"key":"e_1_2_10_57_2","first-page":"245","article-title":"Laparoscopic management of ovarian tumors subsequently diagnosed as malignant","volume":"2","author":"Klinderman G","year":"1996","journal-title":"J Pelvic Surg"},{"key":"e_1_2_10_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03590-X"},{"key":"e_1_2_10_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh323"},{"key":"e_1_2_10_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09738-6"},{"key":"e_1_2_10_61_2","unstructured":"WilailakS.Management of advanced EOC in developing countries. Abstract CS\u20102.5.3. XV111 FIGO World Congress 2006."},{"key":"e_1_2_10_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.153"},{"key":"e_1_2_10_63_2","first-page":"127","article-title":"A DNA vaccine encoding a single chain trimer HLA\u2010A2 linked to human mesothelium peptide generates anti\u2010tumor effects against human mesothelium \u2010expressing tumors","volume":"25","author":"Chien\u2010Fu, Calizo R","year":"2007","journal-title":"Sci Direct"},{"key":"e_1_2_10_64_2","first-page":"18","article-title":"In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients","volume":"122","author":"Tobiasova Z","year":"2007","journal-title":"Sci Dig"},{"key":"e_1_2_10_65_2","first-page":"462","article-title":"Assessment of fusion cells from patient\u2010derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical trial","volume":"99","author":"Koido S","year":"2005","journal-title":"Sci Dig"},{"key":"e_1_2_10_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)70441-6"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6694"},{"key":"e_1_2_10_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(90)90393-Y"},{"key":"e_1_2_10_69_2","article-title":"Adjuvant treatment with monoclonal antibody, Ovarex MAb\u2010B43.13 (OV) targeting CA125, induces robust immune responses associated with prolonged time to relapse in a randomized, placebo\u2010controlled study in patients with advanced epithelial ovarian cancer (EOC)","volume":"21","author":"Ehlen TG","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_10_70_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703342104"},{"key":"e_1_2_10_71_2","first-page":"268","article-title":"Current controversies in ovarian cancer: Maintenance chemotherapy and neoadjuvant chemotherapy as standard care (abstract) 2004","volume":"268","author":"Ozols RF","year":"2004","journal-title":"ASCO Annu Meet"},{"key":"e_1_2_10_72_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102"},{"key":"e_1_2_10_73_2","first-page":"1671","article-title":"Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4+, 2H4+ suppressor T\u2010induced T cells","volume":"48","author":"Bard D","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_10_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2177"},{"key":"e_1_2_10_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13718-X"},{"key":"e_1_2_10_76_2","first-page":"449","article-title":"Gemcitabine\/carboplatin (GC) vs carboplatin(C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomised phase III trial of AGO OVAR the NCIC CTG and the EORTC GCG (abstract)","volume":"23","author":"Pfisterer J","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_10_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-5576(98)00017-3"},{"key":"e_1_2_10_78_2","first-page":"189","volume-title":"Practical Gynaecologic Oncology","author":"Cramer DW","year":"1994"},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703123161102"},{"key":"e_1_2_10_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910490112"},{"key":"e_1_2_10_81_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000255664.48970.e6"},{"key":"e_1_2_10_82_2","first-page":"337","article-title":"Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relations to changing fertility and oral contraceptive use","volume":"6","author":"Dos Santos Silva I","year":"1995","journal-title":"Br J Cancer"},{"key":"e_1_2_10_83_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200003000-00004"},{"key":"e_1_2_10_84_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a008937"},{"key":"e_1_2_10_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390702"},{"key":"e_1_2_10_86_2","first-page":"424","article-title":"Parity, oral contraceptives and the risk of ovarian cancer among carriers of and non\u2010carriers of BRCA1 or BRCA2 mutation","volume":"345","author":"Moden B","year":"2001","journal-title":"N Engl J Med"},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116427"},{"key":"e_1_2_10_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00088-X"},{"key":"e_1_2_10_89_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5909"},{"key":"e_1_2_10_90_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-200412000-00006"},{"key":"e_1_2_10_91_2","first-page":"717","article-title":"Determinants of ovarian cancer risk. 11. Inference regarding pathogenesis","volume":"71","author":"Cramer DW","year":"1983","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_10_92_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117296"},{"key":"e_1_2_10_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90749-8"},{"key":"e_1_2_10_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)92576-5"},{"key":"e_1_2_10_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(98)00439-6"},{"key":"e_1_2_10_96_2","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1001\/jama.1993.03510230051034","article-title":"Tubal ligation, hysterectomy and ovarian cancer \u2013 A prospective study","volume":"270","author":"Hankinson SE","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_10_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705153362001"},{"key":"e_1_2_10_98_2","doi-asserted-by":"publisher","DOI":"10.1086\/301749"},{"key":"e_1_2_10_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.0.CO;2-R"},{"key":"e_1_2_10_100_2","first-page":"3776","article-title":"Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations","volume":"8","author":"Santogopan JM","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_101_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088759"},{"key":"e_1_2_10_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.02.013"},{"key":"e_1_2_10_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.01.039"},{"key":"e_1_2_10_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(92)90110-5"},{"key":"e_1_2_10_105_2","first-page":"223","article-title":"The impact of subspecialty training on the management of advanced ovarian cancer","volume":"47","author":"Eisencop SM","year":"1992","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1447-0756.2009.01049.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1447-0756.2009.01049.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T07:39:01Z","timestamp":1696923541000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1447-0756.2009.01049.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1447-0756.2009.01049.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1447-0756.2009.01049.x","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"value":"1341-8076","type":"print"},{"value":"1447-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}